

NCT02965027 Raw comparison:

Summary:
CHIA has 37 criteria while your personal folder has 48 criteria
Total found criteria: 31/37
Total not Found: 6/37
Total Extra: 11
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male and female Active-duty SMs or Veterans aged   │ Male and female Active-duty Servicemembers (SMs)   │
│ 18 or older who are in good general health         │ or Veterans aged 18 or older who are in good       │
│                                                    │ general health                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of childbearing potential must agree to      │ Participants of childbearing potential must agree  │
│ abstain from sexual relations that could result in │ to abstain from sexual relations that could result │
│ pregnancy or use an effective method of birth      │ in pregnancy or use an effective method of birth   │
│ control acceptable to both participant and the     │ control acceptable to both participant and the     │
│ clinician prescriber during the study Men are not  │ clinician prescriber during the study Participants │
│ required to use contraception during the study     │ who are not of childbearing potential are not      │
│                                                    │ required to use contraception during the study     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participants must have English fluency sufficient  │ Participants must have English fluency sufficient  │
│ to complete study measures                         │ to complete study measures                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in other interventional research     │ Participation in other interventional research     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of penetrating head injury                 │ History of penetrating head injury                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of TBI more severe than mild by DVBIC      │ History of TBI more severe than mild by DVBIC      │
│ criteria                                           │ criteria                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HAs of any kind of moderate or severe intensity on │ HAs of any kind of moderate or severe intensity on │
│ an average of more than 2 days per month preceding │ an average of more than 4 days per month preceding │
│ the concussive trauma                              │ the concussive trauma                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute or serious medical illness or unstable       │ Acute or serious medical illness or unstable       │
│ chronic medical illness (e g unstable angina       │ chronic medical illness (e g unstable angina       │
│ myocardial infarction within 6 months congestive   │ myocardial infarction within 6 months congestive   │
│ heart failure clinically significant or concerning │ heart failure clinically significant or concerning │
│ cardiac arrhythmias preexisting hypotension        │ cardiac arrhythmias preexisting hypotension        │
│ [systolic blood pressure<110] or orthostatic       │ \[systolic blood pressure\<110\] or orthostatic    │
│ hypotension [systolic drop >20 mm Hg after 2 min   │ hypotension \[systolic drop \>20 mm Hg after 2 min │
│ standing accompanied by lightheadedness] chronic   │ standing accompanied by lightheadedness\] chronic  │
│ renal or hepatic failure acute pancreatitis        │ renal or hepatic failure or acute pancreatitis The │
│ Meniere's disease or diagnosed but untreated sleep │ eligibility of potential participants having acute │
│ apnea) The eligibility of potential participants   │ serious and/or chronic medical illnesses other     │
│ having acute serious and/or chronic medical        │ than those listed will be evaluated on a case-by-  │
│ illnesses other than those listed will be          │ case basis by a study physician physician          │
│ evaluated on a case-by-case basis by a study       │ assistant - certified (PA-C) or advanced           │
│ physician PA-C or ARNP                             │ registered nurse practitioner (ARNP)               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of prazosin or other alpha-1 antagonist        │ Use of prazosin or other alpha-1 antagonist        │
│ (including but not limited to alfuzosin doxazosin  │ (including but not limited to alfuzosin doxazosin  │
│ silodosin tamsulosin terazosin) for any purpose in │ silodosin tamsulosin terazosin) for any purpose in │
│ the 2 weeks prior to initial screen (P1) visit and │ the 2 weeks prior to initial screen (P1) visit and │
│ prohibited throughout the study                    │ prohibited throughout the study                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Allergy or previous adverse reaction to prazosin   │ Allergy or previous adverse reaction to prazosin   │
│ or other alpha-1 antagonist                        │ or other alpha-1 antagonist                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active psychosis or psychotic disorder severe      │ Active psychosis or psychotic disorder severe      │
│ depression (as determined per clinician prescriber │ depression (as determined per clinician prescriber │
│ judgment) severe psychiatric instability or severe │ judgment) severe psychiatric instability or severe │
│ situational life crisis (including evidence of     │ situational life crisis (including evidence of     │
│ being actively suicidal or homicidal)              │ being actively suicidal or homicidal)              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Meets Diagnostic and Statistical Manual of Mental  │ Meets Diagnostic and Statistical Manual of Mental  │
│ Disorders 5th Edition (DSM-5) criteria for any     │ Disorders 5th Edition (DSM-5) criteria for any     │
│ Substance Use Disorder except caffeine-related     │ Substance Use Disorder except caffeine-related     │
│ disorders or tobacco-related disorders             │ disorders or tobacco-related disorders             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of delirium within the prior 3 months      │ History of delirium within the prior 3 months      │
│ epilepsy stroke dementia psychotic disorder or     │ epilepsy stroke dementia psychotic disorder or     │
│ bipolar disorder                                   │ bipolar disorder                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Structural brain abnormalities on any prior        │ Structural brain abnormalities on any prior        │
│ imaging with associated clinically evident         │ imaging with associated clinically evident         │
│ manifestations                                     │ manifestations                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current participation in transcranial magnetic     │ Current participation in transcranial magnetic     │
│ stimulation studies                                │ stimulation studies                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of childbearing potential must not be        │ Women of childbearing potential must not be        │
│ pregnant planning to become pregnant during the    │ pregnant planning to become pregnant during the    │
│ study period or nursing                            │ study period or nursing                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in a HA support group or other       │ Participation in a HA support group or other       │
│ activity such as meditation or yoga intended to    │ activity such as meditation or yoga intended to    │
│ mitigate HA or other chronic pain must be stable   │ mitigate HA or other chronic pain must be stable   │
│ at least 4 weeks prior to beginning the initial    │ at least 4 weeks prior to beginning the initial    │
│ screen (P1) visit and may not be started during    │ screen (P1) visit and may not be started during    │
│ the study                                          │ the study                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Failure to record HA data for at least 80% of days │ Failure to record HA data for at least 80% of days │
│ during the Screening Period                        │ during the Screening Period                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Not suitable for study per clinician judgement     │ Not suitable for study per clinician judgement     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The use of HA rescue or symptom-relieving          │ The use of HA rescue or symptom-relieving          │
│ medications will be allowed during the study This  │ medications will be allowed during the study This  │
│ includes triptans ergotamines opioids simple       │ includes triptans ergotamines opioids simple       │
│ analgesics (e g acetaminophen aspirin or non-      │ analgesics (e g acetaminophen aspirin or non-      │
│ steroidal anti-inflammatories [NSAIDS] and         │ steroidal anti-inflammatories \[NSAIDS\] and       │
│ combination analgesics Their use will be recorded  │ combination analgesics Their use will be recorded  │
│ on the concurrent medication CRF during the        │ on the concurrent medication case report form      │
│ Preliminary Screening Period (P1) and throughout   │ (CRF) during the Preliminary Screening Period (P1) │
│ the remainder of the study Randomization of        │ and throughout the remainder of the study          │
│ participants will be stratified based on whether   │ Randomization of participants will be stratified   │
│ their use of HA medications meets ICHD-3 beta      │ based on whether their use of HA medications meets │
│ criteria for overuse of these medications as       │ International Classification of Headache Disorders │
│ described in section 5 5 below                     │ 3rd addition (ICHD-3 beta) criteria for overuse of │
│                                                    │ these medications as described in section 5 5      │
│                                                    │ below                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Opioid Medications Use of opioids for treatment of │ Opioid Medications Use of opioids for treatment of │
│ HA or non-HA-related pain or for any other purpose │ HA or non-HA-related pain or for any other purpose │
│ is allowed during the study Any opioid use would   │ is allowed during the study Any opioid use would   │
│ ideally be excluded due to potential confounding   │ ideally be excluded due to potential confounding   │
│ effects on interpretation of response to treatment │ effects on interpretation of response to treatment │
│ However in this population particularly in         │ However in this population particularly in         │
│ Veterans with chronic pain or undergoing minor     │ Veterans with chronic pain or undergoing minor     │
│ orthopedic or dental procedures opioid use is      │ orthopedic or dental procedures opioid use is      │
│ common Use of opioids including frequency and dose │ common Use of opioids including frequency and dose │
│ will be recorded on the concurrent medication CRF  │ will be recorded on the concurrent medication CRF  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other Medications Participants who are taking      │ Other Medications Participants who are using other │
│ other medications on a routine basis must be on a  │ medications or treatments on a routine basis must  │
│ stable dose for at least 4 weeks prior to the      │ be on a stable dose for at least 4 weeks prior to  │
│ Preliminary Screening Period (P1) and must intend  │ the Preliminary Screening Period (P1) and must     │
│ to continue the medication at the same regimen for │ intend to continue the medication at the same      │
│ the duration of the trial unless lack of efficacy  │ regimen for the duration of the trial unless lack  │
│ safety or tolerability dictates otherwise The      │ of efficacy safety or tolerability dictates        │
│ following medications are not excluded             │ otherwise The following medications and treatments │
│                                                    │ are not excluded                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Psychoactive drugs (for example anticonvulsants    │ Psychoactive drugs (for example anticonvulsants    │
│ benzodiazepines antidepressants                    │ benzodiazepines antidepressants                    │
│ sedative/hypnotics)                                │ sedative/hypnotics)                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Antihypertensive medications (including beta-      │ Antihypertensive medications (including beta-      │
│ blockers calcium channel blockers angiotensin      │ blockers calcium channel blockers angiotensin      │
│ converting enzyme [ACE] inhibitors and angiotensin │ converting enzyme \[ACE\] inhibitors and           │
│ receptor blockers)                                 │ angiotensin receptor blockers)                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The use of magnesium in any dose that is           │ The use of magnesium in any dose that is           │
│ prescribed for the purpose of HA prevention or     │ prescribed for the purpose of HA prevention or     │
│ treatment must be stable for at least 4 weeks The  │ treatment The incidental use of magnesium in       │
│ incidental use of magnesium in multi-vitamins      │ multi-vitamins laxatives etc is permissible but    │
│ laxatives etc is permissible but must be           │ must be documented                                 │
│ documented                                         │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hormones (for example testosterone estrogen or     │ Hormones (for example testosterone estrogen or     │
│ progesterone) in any form                          │ progesterone) in any form                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The use of butalbital in any form within 4 weeks   │ The use of butalbital in any form within 4 weeks   │
│ of beginning the Preliminary Screening Period (P1) │ of beginning the Preliminary Screening Period (P1) │
│ through the end of the participant's study         │ through the end of the participant's study         │
│ involvement is exclusionary                        │ involvement is exclusionary                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participants who have been taking trazodone will   │ Participants who have been taking trazodone will   │
│ undergo a 2-week washout period before the         │ undergo a 2-week washout period before the         │
│ Preliminary Screening Period (P1 visit) Combining  │ Preliminary Screening Period (P1 visit) Combining  │
│ prazosin and trazodone may increase the risk of    │ prazosin and trazodone may increase the risk of    │
│ priapism We have decided to begin the washout      │ priapism We have decided to begin the washout      │
│ period before the Preliminary Screening Period in  │ period before the Preliminary Screening Period in  │
│ order to remove any confounding variables while on │ order to remove any confounding variables while on │
│ the headache log and actigraphy                    │ the headache log and actigraphy                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Sildenafil (Viagra) tadalafil (Cialis) vardenafil  │ Sildenafil (Viagra) tadalafil (Cialis) vardenafil  │
│ (Levitra) and avanafil (Stendra) will not be       │ (Levitra) and avanafil (Stendra) will not be       │
│ permitted during the study drug dose Titration     │ permitted during the study drug dose Titration     │
│ Period because of increased risk of hypotension in │ Period because of increased risk of hypotension in │
│ combination with alpha-1 blockers but will be      │ combination with alpha-1 blockers but will be      │
│ allowed at half the usual starting dose following  │ allowed at half the usual starting dose following  │
│ the study drug dose Titration Period per VA        │ the study drug dose Titration Period per VA        │
│ prescribing guidelines                             │ prescribing guidelines                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of supplements containing nitrates and         │ Use of supplements containing nitrates and         │
│ supplements containing stimulants (such as         │ supplements containing stimulants (such as         │
│ ephedra) are exclusionary in the two weeks prior   │ ephedra) are exclusionary in the two weeks prior   │
│ to initial screen (P1) visit and prohibited        │ to initial screen (P1) visit and prohibited        │
│ throughout the study Participants who take these   │ throughout the study Participants who take these   │
│ supplements will be asked to discontinue them for  │ supplements will be asked to discontinue them for  │
│ a minimum of two weeks before the Preliminary      │ a minimum of two weeks before the Preliminary      │
│ Screening Period (P1 visit)                        │ Screening Period (P1 visit)                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of prescribed stimulants (such as amphetamine  │ Use of prescribed stimulants (such as amphetamine  │
│ or dextroamphetamine containing medications) is    │ or dextroamphetamine containing medications) is    │
│ exclusionary in the 2 weeks prior to the initial   │ exclusionary in the 2 weeks prior to the initial   │
│ screen (P1) visit and prohibited throughout the    │ screen (P1) visit and prohibited throughout the    │
│ study Participants who take these medications will │ study Participants who take these medications will │
│ be asked to discontinue them for a minimum of 2    │ be asked to discontinue them for a minimum of 2    │
│ weeks before the Preliminary Screening Period      │ weeks before the Preliminary Screening Period      │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                  │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ History of blast and/or impact head trauma mTBI meeting Defense and Veterans Brain Injury Center     │
│ (DVBIC) mTBI criteria which define mTBI as an injury to the head causing at least one of the         │
│ following alteration in consciousness (for up to 24 hours after the injury) loss of consciousness    │
│ 0-30 minutes and/or post-traumatic amnesia up to 1 day post-injury If available the Glasgow Coma     │
│ Scale score must be 13-15 and head imaging findings (if imaging was performed) must be negative      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Frequent HAs that started within 3months after a head injury The HAs either 1) must last 4 or more   │
│ hours a day and reach a moderate to severe intensity at any point during the headache or 2) may be   │
│ of any severity or duration if the participant takes a triptan or ergotamine HAs meeting these       │
│ criteria must have been present on average at least 8 days per 4-week period starting within 30 days │
│ after head injury and occurring by self-report for at least 3 months prior to the Initial Screening  │
│ Visit The 4-week HA frequency/severity criteria must be confirmed during the Preliminary Screening   │
│ Period                                                                                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Diagnosis of a primary or secondary HA disorder other than PTHA                                      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Lifetime history of 5 or more migraine or probable migraine headaches pre-dating mTBI                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Continuous HAs of any kind (i e persistent daily HAs with no HA-free period less than 8 hours        │
│ between attacks)                                                                                     │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ The "as-needed" (prn) use of psychoactive and other drugs such as antibiotics is not excluded        │
│ however such use must be discussed with a clinician prescriber and documented                        │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ HAs either 1) must last 4 or more hours a day and reach a moderate to severe intensity at any point  │
│ during the headache or 2) may be of any severity or duration if the participant takes a medication   │
│ or other agent in an effort to stop or treat a headache                                              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ o Mild TBI is defined as an injury to the head causing at least one of the following alteration in   │
│ consciousness (for up to 24 hours after the injury) loss of consciousness (0-30 minutes) and/or      │
│ post-traumatic amnesia (up to 1 day post-injury) If available the Glasgow Coma Scale score must be   │
│ 13-15 and head imaging findings (if imaging was performed) must be negative                          │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Frequent headaches (HAs) that started within 3 months after a head injury or marked worsening (a     │
│ two-fold or greater increase in frequency and/or severity) of pre-existing headaches within 3 months │
│ of head injury                                                                                       │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ The "as-needed" (prn) use of any non-exclusionary medications is allowed however such use must be    │
│ discussed with a clinician prescriber and documented                                                 │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ HAs meeting these criteria must have been present on average at least 8 days per 4-week period and   │
│ occurring at a stable level by self-report for at least 3 months prior to the Initial Screening      │
│ Visit The 4-week HA frequency/severity criteria must be confirmed during the Preliminary Screening   │
│ Period                                                                                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Medication-and other Treatment-Related Considerations                                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ A primary non migraine and/or tension-type HA disorder (for example hemicrania continua cluster)     │
│ that accounts for the majority of current symptoms                                                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Onabotulinum toxin A and nerve block injections for the purpose of HA prevention are permissible if  │
│ the treatment response has been stable during the two most recent treatment cycles                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ History of blast and/or impact head trauma mild traumatic brain injury (mTBI) meeting Defense and    │
│ Veterans Brain Injury Center (DVBIC) mTBI criteria                                                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Cannabis The use of cannabis in any form is not excluded unless its use meets criteria for Cannabis  │
│ Use Disorder All use of cannabis will be documented                                                  │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                    │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛